Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Fondazione per la ricerca sulla Fibrosi Cistica |
---|---|
Information provided by: | Fondazione per la ricerca sulla Fibrosi Cistica |
ClinicalTrials.gov Identifier: | NCT00687466 |
The purpose of this study is evaluate whether the anticipated use of glargine in CF patients with glucose intolerance may prevent the worsening of nutritional status and pulmonary function.
Condition | Intervention | Phase |
---|---|---|
Cystic Fibrosis Glucose Intolerance |
Drug: Insulin |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | Phase 3 Study on the Efficacy of Slow Release Insulin in Cystic Fibrosis Patients With Glucide Intolerance and Clinical Decay |
Estimated Enrollment: | 70 |
Study Start Date: | August 2005 |
Estimated Study Completion Date: | December 2009 |
Estimated Primary Completion Date: | August 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Insulin yes
|
Drug: Insulin
Insulin Glargine will be administered subcutaneously at the dosage of 0.1 U/Kg/die for three months. In case no hypoglycemic episodes occur during this period, the dosage will be increased to 0.15 U/Kg/die in occasion of the first control (T1) and will be scheduled for other three months. If even during this latter period no cases no hypoglycemic episodes occur, at the second control (T2) the dosage will be increased to the maximum of 0.2/U/Kg/die. It is generally accepted that the final dosage of glargine can be tailored to each patient, but it should be maintained between 0.1 and 0.2 U/Kg/die. Glargine should be administered once daily in the morning and always at the same hour. |
2: No Intervention
Insulin no
|
Diabetes mellitus may often complicate the cystic fibrosis course, and it is usually preceded by a condition defined as glucose intolerance, during which a significant decay of patient's general conditions is observed. A slow release insulin (glargine) has become available in the market for diabetic patients: its characteristics allow for a single daily dose, and no need of repeated daily monitoring of glycemia.
In this randomized controlled clinical trial we evaluate whether the anticipated use of glargine in CF patients with glucose intolerance may prevent the worsening of nutritional status and pulmonary function.
Eligible patients who will accept to participate to this study will be randomly allocated in the group who will or will not receive glargine as additional supportive therapy. Patients will in any case continue the CF therapy prescribed by their treating physicians and their usual diet. All the patients will be evaluated every three months to assess their nutritional, pulmonary and glycometabolic status. The follow-up will continue until the 18th month after the study entry.
Ages Eligible for Study: | 10 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
At least one of the following conditions:
Exclusion Criteria:
Contact: Riccardo Haupt, MD | 39-010-563-6301 | riccardohaupt@ospedale-gaslini.ge.it |
Contact: Rosaria Casciaro, MD | 39-010-563-6564 | rosariacasciaro@ospedale-gaslini.ge.it |
Italy | |
Bambino Gesù Hospital CF Center | Recruiting |
Roma, Italy | |
Contact: Vincenzina Lucidi, MD lucidi@opbg.net | |
Policlinico Umberto I. CF Center | Recruiting |
Roma, Italy | |
Contact: Serena Bertasi, MD s.bertasi@policlinicoumberto1.it | |
Pediatric Department G.De Cristina Hospital CF Center | Recruiting |
Palermo, Italy | |
Contact: Gabriella Traverso g.traverso@libero.it | |
Ospedale Maggiore Policlinico, Adult CF Center | Recruiting |
Milano, Italy | |
Contact: Alice Monti mariaalice.monti@unimi.it | |
Pediatric Department, General Hospital,CF Center | Recruiting |
Cerignola (Foggia), Italy | |
Contact: Luigi Ratclif ratclif@freemail.it | |
Pediatric Department, Federico II University, Pediatric CF Center | Recruiting |
Napoli, Italy | |
Contact: Valeria Raia raia@unina.it |
Principal Investigator: | Laura Minicucci, MD | G.Gaslini Institute Pediatric Department CF Center |
Responsible Party: | Pediatric Department,CF Center Genova, G.Gaslini Institute, Genova, Italy ( Laura Minicucci. MD, Genova CF Center Head ) |
Study ID Numbers: | FFC #21/2006, eudraCT number 2005-002135-27, IGG-FC-G-01 |
Study First Received: | May 27, 2008 |
Last Updated: | May 29, 2008 |
ClinicalTrials.gov Identifier: | NCT00687466 |
Health Authority: | Italy: The Italian Medicines Agency |
Cystic Fibrosis Glucose Intolerance |
Metabolic Diseases Fibrosis Glucose Intolerance Insulin Digestive System Diseases Hyperglycemia Cystic Fibrosis Respiratory Tract Diseases |
Genetic Diseases, Inborn Lung Diseases Glargine Pancreatic Diseases Infant, Newborn, Diseases Metabolic disorder Glucose Metabolism Disorders Cystic fibrosis |
Hypoglycemic Agents Pathologic Processes Physiological Effects of Drugs Pharmacologic Actions |